Bajaj Healthcare Ltd. has reported a strong financial turnaround in Q3 FY25, swinging to a net profit of ₹11.7 crore, compared to a net loss of ₹2.2 crore in the same quarter last year. The company’s revenue surged 13.1% YoY to ₹122.8 crore, up from ₹108.6 crore in Q3 FY24, driven by steady demand for active pharmaceutical ingredients (APIs) and bulk drugs.
Key Financial Highlights (Q3 FY25)
- Revenue: ₹122.8 crore (+13.1% YoY)
- Net Profit: ₹11.7 crore (vs. ₹2.2 crore loss in Q3 FY24)
- EBITDA: ₹21.7 crore (+10.7% YoY)
- EBITDA Margin: 17.7%, slightly lower than 18.1% last year
Despite the positive earnings performance, Bajaj Healthcare’s stock closed down 4.47% at ₹595.60 on the BSE, ahead of the results announcement.
Strategic Growth & Market Presence
Bajaj Healthcare, a major exporter of APIs to over 50 countries, caters to the pharmaceutical, nutraceutical, and food industries. The company is actively expanding its portfolio of specialty APIs and finished dosage formulations to drive long-term growth and strengthen its global market position.
